title: Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
abstract: OBJECTIVE
  Once-daily extended-release (XR) trospium chloride has been evaluated for the treatment of overactive bladder syndrome (OAB) in two 12-week randomized, double-blind, placebo-controlled studies. This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium XR.
  
  
  METHODS
  Following double-blind treatment, subjects with OAB could enter the open-label period, during which they received trospium 60 mg XR once daily for 36 weeks. The primary efficacy variables were changes from baseline in the number of toilet voids and urgency urinary incontinence (UUI) episodes per day at Week 48. Adverse events (AEs) were also recorded.
  
  
  RESULTS
  Of the 1,027 subjects who completed double-blind treatment, 944 (92%) continued into the open-label period (placebo-to-trospium, N = 483; trospium-to-trospium, N = 461); 332 (68.7%) and 335 (72.7%), respectively, completed the open-label period. At Week 48, the mean change from baseline in the number of toilet voids/day was -3.21 in the placebo-to-trospium group and -3.35 in the trospium-to-trospium group, and the median change from baseline in the number of UUI episodes/day was -2.33 in both groups. Efficacy was maintained relative to Week 12 in trospium-to-trospium subjects, while improvement was seen following trospium initiation in placebo-to-trospium subjects. Improvement from baseline was also observed on secondary efficacy parameters at Week 48. Trospium was well tolerated; dry mouth and constipation were the most common class treatment-emergent AEs. Central nervous system AEs were rare and did not increase with long-term treatment.
  
  
  CONCLUSIONS
  Long-term treatment of OAB with once-daily trospium 60 mg XR is effective and well tolerated.
authors.affiliation: Western Clinical Research Inc., Torrance, California 90505, USA. wewedoc@aol.com
authors.forename: Norman R
authors.initials: NR
authors.lastname: Zinner
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
authors.forename: David R
authors.initials: DR
authors.lastname: Staskin
authors.forename: Paul F
authors.initials: PF
authors.lastname: Siami
authors.forename: Peter K
authors.initials: PK
authors.lastname: Sand
authors.forename: Michael G
authors.initials: MG
authors.lastname: Oefelein
mesh_terms: D000368:Aged; D001561:Benzilates; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009662:Nortropanes / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000294:innervation; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D053202:Urinary Incontinence, Urge / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D001561:Benzilates; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D009662:Nortropanes; C003330:trospium chloride